OBJECTIVES: To identify prevalence and risk factors for exposure to drug-disease interactions included in the Healthcare Effectiveness Data and Information Set (HEDIS) Drug-Disease Interaction (Rx-DIS) measure. DESIGN: Cross-sectional retrospective database analysis. SETTING: Outpatient clinics within the Department of Veterans Affairs (VA). PARTICIPANTS: Individuals aged 65 and older who received VA outpatient care between October 1, 2003, and September 30, 2006. MEASUREMENTS: Rx-DIS exposure based on the HEDIS measure was identified in VA patients with dementia, falls, and chronic renal failure using VA pharmacy and administrative databases. Factors associated with Rx-DIS exposure were examined, including demographic, health status, and access-to-care factors, including VA outpatient health services use and copayment status. RESULTS: Of the 305,041 older veterans who met criteria for inclusion, the 1-year prevalence of Rx-DIS exposure was 15.2%; prevalence was 20.2% for dementia, 16.2% for falls, and 8.5% for chronic renal failure. Patients with high disease burden (physical, psychiatric, number of medications) were significantly more likely to have Rx-DIS exposure, regardless of condition. Hispanics and individuals with no copayments were more likely to have Rx-DIS exposure than whites or those with required copayments. There was variation in other predictors based on the type of Rx-DIS. CONCLUSION: The prevalence of Rx-DIS was common in older VA outpatients. Future studies should examine the risk of Rx-DIS exposure on health outcomes using separate analyses for each type of Rx-DIS separately before combining all Rx-DIS into a single measure of exposure. Studies that examine the effectiveness of interventions to reduce Rx-DIS exposure will also be helpful in improving the quality of care for older adults.
OBJECTIVES: To identify prevalence and risk factors for exposure to drug-disease interactions included in the Healthcare Effectiveness Data and Information Set (HEDIS) Drug-Disease Interaction (Rx-DIS) measure. DESIGN: Cross-sectional retrospective database analysis. SETTING:Outpatient clinics within the Department of Veterans Affairs (VA). PARTICIPANTS: Individuals aged 65 and older who received VA outpatient care between October 1, 2003, and September 30, 2006. MEASUREMENTS: Rx-DIS exposure based on the HEDIS measure was identified in VA patients with dementia, falls, and chronic renal failure using VA pharmacy and administrative databases. Factors associated with Rx-DIS exposure were examined, including demographic, health status, and access-to-care factors, including VA outpatient health services use and copayment status. RESULTS: Of the 305,041 older veterans who met criteria for inclusion, the 1-year prevalence of Rx-DIS exposure was 15.2%; prevalence was 20.2% for dementia, 16.2% for falls, and 8.5% for chronic renal failure. Patients with high disease burden (physical, psychiatric, number of medications) were significantly more likely to have Rx-DIS exposure, regardless of condition. Hispanics and individuals with no copayments were more likely to have Rx-DIS exposure than whites or those with required copayments. There was variation in other predictors based on the type of Rx-DIS. CONCLUSION: The prevalence of Rx-DIS was common in older VA outpatients. Future studies should examine the risk of Rx-DIS exposure on health outcomes using separate analyses for each type of Rx-DIS separately before combining all Rx-DIS into a single measure of exposure. Studies that examine the effectiveness of interventions to reduce Rx-DIS exposure will also be helpful in improving the quality of care for older adults.
Authors: Mary Jo V Pugh; Laurel A Copeland; John E Zeber; Joyce A Cramer; Megan E Amuan; Jose E Cavazos; Lewis E Kazis Journal: Epilepsia Date: 2005-11 Impact factor: 5.864
Authors: Alfredo J Selim; Dan R Berlowitz; Graeme Fincke; Amy K Rosen; Xinhua S Ren; Cindy L Christiansen; Zhongxhiao Cong; Austin Lee; Lewis Kazis Journal: Med Care Date: 2002-03 Impact factor: 2.983
Authors: Joseph T Hanlon; Kenneth E Schmader; Chad Boult; Margaret B Artz; Cynthia R Gross; Gerda G Fillenbaum; Christine M Ruby; Judith Garrard Journal: J Am Geriatr Soc Date: 2002-01 Impact factor: 5.562
Authors: Kenneth E Schmader; Joseph T Hanlon; Carl F Pieper; Richard Sloane; Christine M Ruby; Jack Twersky; Susan Dove Francis; Laurence G Branch; Catherine I Lindblad; Margaret Artz; Morris Weinberger; John R Feussner; Harvey Jay Cohen Journal: Am J Med Date: 2004-03-15 Impact factor: 4.965
Authors: Walid F Gellad; Chester B Good; Megan E Amuan; Zachary A Marcum; Joseph T Hanlon; Mary Jo V Pugh Journal: J Am Geriatr Soc Date: 2012-06-21 Impact factor: 5.562
Authors: Sherrie L Aspinall; Xinhua Zhao; Todd P Semla; Francesca E Cunningham; Allison M Paquin; Mary Jo Pugh; Kenneth E Schmader; Roslyn A Stone; Joseph T Hanlon Journal: J Am Geriatr Soc Date: 2014-12-23 Impact factor: 5.562
Authors: J T Hanlon; S Perera; A B Newman; J M Thorpe; J M Donohue; E M Simonsick; R I Shorr; D C Bauer; Z A Marcum Journal: J Clin Pharm Ther Date: 2017-01-22 Impact factor: 2.512
Authors: Una E Makris; Mary Jo Pugh; Carlos A Alvarez; Dan R Berlowitz; Barbara J Turner; KoKo Aung; Eric M Mortensen Journal: Am J Med Sci Date: 2015-10 Impact factor: 2.378
Authors: Michael A Steinman; Yinghui Miao; W John Boscardin; Kiya D R Komaiko; Janice B Schwartz Journal: J Gen Intern Med Date: 2014-07-08 Impact factor: 5.128
Authors: Mary Jo V Pugh; Zachary A Marcum; Laurel A Copeland; Eric M Mortensen; John E Zeber; Polly H Noël; Dan R Berlowitz; John R Downs; Chester B Good; Carlos Alvarez; Megan E Amuan; Joseph T Hanlon Journal: Drugs Aging Date: 2013-08 Impact factor: 3.923